2. Apoptosis Autophagy Metabolic Enzyme/Protease
  3. RIP kinase Autophagy Indoleamine 2,3-Dioxygenase (IDO) Ferroptosis Necroptosis
  4. Necrostatin-1

Necrostatin-1  (Synonyms: Nec-1; ネクロスタチン-1)

製品番号: HY-15760 純度: 99.89%
COA 取扱説明書 Technical Support

Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM). Necrostatin-1 is also an IDO inhibitor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 4311-88-0

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 41 在庫あり
Solution
10 mM * 1 mL in DMSO USD 41 在庫あり
Solid
5 mg $38 在庫あり
10 mg $60 在庫あり
25 mg $120 在庫あり
50 mg $180 在庫あり
100 mg $228 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 508 publication(s) in Google Scholar

Other Forms of Necrostatin-1:

Necrostatin-1 関連抗体

Top Publications Citing Use of Products

顧客検証

Cell Proliferation/Viability Assay
WB

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Jul;21(7):1473-1491.  [Abstract]

    Necrostatin-1 (Nec-1, 10 μM) rescues the loss of neuronal cell viability induced by Psmd14 knockdown.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Aug 27;12(1):47.  [Abstract]

    Cell death induced by HOXC10 inhibition plus TTI-101 cotreatment was rescued by ferroptosis inhibitors. Cells with or without knockdown of HOXC10 were pretreated with HOXC10 TTI-101 for 12 h and then treated the indicated cell death inhibitors (3-MA-1 mmol/L, Necrostatin-1-20 μmol/L, Ferrostatin-1-2 μmol/L, Z-VAD-FMK-10 μmol/L, Glutathione-1 mmol/L, Deferoxamine (DFO-100 μmol/L)) for an additional 72 h. Effect on ferroptosis inhibitors rescuing cell death was assessed by cell viability assays.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun;11(21):e2309002.  [Abstract]

    Necrostatin-1 (Nec-1; 25 μM; 24 h) significantly restores cell viability in THBS1-knockdown HTR8/SVneo cells.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun;11(21):e2309002.  [Abstract]

    Necrostatin-1 (Nec-1; 25 μM; 24 h) significantly restores proliferative capacity in THBS1-knockdown HTR8/SVneo cells.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun;11(21):e2309002.  [Abstract]

    Necrostatin-1 (Nec-1; 25 μM; 24 h) significantly reduces protein expression of RIPK1, p-RIPK3, RIPK3, p-MLKL, and DAMP molecules in THBS1-knockdown cells.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2023 May 14.

    The viability of MC38 cells treated with PAD@MS for 48 h in the presence or absence of 10 µM Ferr-1 (Ferrostatin-1), 20 µM Nec-1 (Necrostatin-1), 10 µM Z-VAD-FMK, and 1 mM NAC.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 Apr;18(4):726-744.  [Abstract]

    Necrostatin-1 (Nec-1, 30 µM; 6.5 h) blocks TSZ-induced increases in p-MLKL, SQSTM1, and LC3-II levels in L929 cells.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Braz J Med Biol Res. 2018 Nov 23;52(1):e7844.  [Abstract]

    Representative western blot graphs showing the effects of tumor necrosis factor-α (TNF-α) on the protein expression levels of specific marker proteins receptor interacting protein kinase (RIPK3), mixed lineage kinase domain-like protein (MLKL) and p-MLKL, caspase 3 and cleaved caspase 3, and b-actin in MC3T3-E1 cells with TNF-α, Nec-1 or Z-IETD-FMK treatment.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Exp Neurol. 2017 Sep:295:116-124.  [Abstract]

    Nec-1 treatment inhibits RIP1-RIP3, p-DRP1 activation and reduces the expression of NLRP3 and cleaved caspase-1 at 24 h after SAH. Representative Western blots showing levels of RIP1, RIP3, p-DRP1, DRP1, NLRP3 and cleaved caspase-1.

    Necrostatin-1 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Nov 23;7(1):16111.  [Abstract]

    RIP1 does not mediate TNFα-induced apoptosis in RIP3 knockdown L929 cells. Nec-1 does not block the TNFα-induced death of RIP3 knockdown L929 cells. The cells are infected with the RIP3 shRNA or the negative control shRNA lentivirus, and western blotting is performed to determine RIP3 knockdown efficiency.

    RIP kinase アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    RIPK1 RIPK2 RIPK3

    Indoleamine 2,3-Dioxygenase (IDO) アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    IDO1 IDO2 IDO

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM). Necrostatin-1 is also an IDO inhibitor[1].

    IC50 & Target

    EC50: 182 nM (RIP1 kinase)[1]
    Cellular Effect
    Cell Line Type Value Description References
    HT-29 CC50
    > 50 μM
    Compound: 1
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by celltiter glo assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by celltiter glo assay
    		[PMID: 37494773]
    HT-29 EC50
    > 10 μM
    Compound: Nec-1
    Anti-necroptotic activity against TSZ-treated human HT-29 cells assessed as cell survival incubated for 4 hrs followed by fresh medium replacement without compound by CCK8 assay
    Anti-necroptotic activity against TSZ-treated human HT-29 cells assessed as cell survival incubated for 4 hrs followed by fresh medium replacement without compound by CCK8 assay
    		[PMID: 39180479]
    Jurkat EC50
    0.05 μM
    Compound: (+/-)-1
    Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat T cells
    Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat T cells
    		[PMID: 18467094]
    Jurkat EC50
    0.49 μM
    Compound: 1
    Effective concentration required for inhibition of necroptosis in FADD deficient Jurkat T cells treated with TNF-alpha
    Effective concentration required for inhibition of necroptosis in FADD deficient Jurkat T cells treated with TNF-alpha
    		[PMID: 16153840]
    Jurkat EC50
    0.49 μM
    Compound: Nec-1
    Anti-necroptic activity in TNFalpha-induced human Jurkat cells assessed as cell viability pretreated for 24 hrs followed by TNFalpha induction by Cell-titer-glo assay
    Anti-necroptic activity in TNFalpha-induced human Jurkat cells assessed as cell viability pretreated for 24 hrs followed by TNFalpha induction by Cell-titer-glo assay
    		[PMID: 36724216]
    Jurkat EC50
    0.54 μM
    Compound: Nec-1
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability by MTT assay
    		[PMID: 38199165]
    Jurkat EC50
    182 nM
    Compound: 1
    Inhibition of endogenous RIP1 autophosphorylation in human Jurkat cells
    Inhibition of endogenous RIP1 autophosphorylation in human Jurkat cells
    		[PMID: 18408713]
    Jurkat EC50
    490 nM
    Compound: 1
    Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells
    Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells
    		[PMID: 18408713]
    Jurkat IC50
    494 nM
    Compound: 1, Nec-1
    Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cell deficient in FADD assessed as cell viability after 30 hrs by ATP based viability assay in presence of TNFalpha
    Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cell deficient in FADD assessed as cell viability after 30 hrs by ATP based viability assay in presence of TNFalpha
    		[PMID: 16408008]
    Sf9 IC50
    182 nM
    Compound: Necrostatin-1
    Inhibition of recombinant human GST-fused RIPK1 (1 to 497 residues) expressed in baculovirus infected insect Sf9 cells in presence of 32P-gamma-ATP after 30 mins by autoradiogram-based Western blot method
    Inhibition of recombinant human GST-fused RIPK1 (1 to 497 residues) expressed in baculovirus infected insect Sf9 cells in presence of 32P-gamma-ATP after 30 mins by autoradiogram-based Western blot method
    		[PMID: 28280261]
    体外実験

    Necrostatin-1 (Nec-1) efficiently inhibits the TNFα-induced necrotic death of L929 cells, which does not require exogenous caspase inhibitors[1].
    Necrostatin-1 (Nec-1) prevents radiocontrast media (RCM)-induced dilation of peritubular capillaries, suggesting a novel role unrelated to cell death for the RIP1 kinase domain in the regulation of microvascular hemodynamics and pathophysiology of contrast-induced AKI (CIAKI)[2].
    Necrostatin-1 (Nec-1) (30 μM) increases the survival of cardiomyocyte progenitor cell (CMPCs) by inhibiting necrotic cell death[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Necrostatin-1 関連抗体
    体内実験

    Necrostatin-1 (Nec-1) induces tubular bilation and affects the kinetics of the dilation of peritubular capillaries after RCM application. Upon a single intraperitoneal application of a single dose of Necrostatin-1 (1.65 mg/kg body weight, i.p.) 15 minutes before RCM, the return to baseline levels is prevented within the observation period[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    259.33

    分子式

    C13H13N3OS
    CAS 番号
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C(C(CC1=CNC2=C1C=CC=C2)N3)N(C)C3=S
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 125 mg/mL (482.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.8561 mL 19.2805 mL 38.5609 mL
    5 mM 0.7712 mL 3.8561 mL 7.7122 mL
    10 mM 0.3856 mL 1.9280 mL 3.8561 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (8.02 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (8.02 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  0.5% CMC-Na/saline water

      Solubility: 12.5 mg/mL (48.20 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.89%

    COA (254 KB) RP-HPLC (242 KB) Elemental Analysis Report (112 KB)

    取扱説明書 (2659 KB)
    参考文献
    細胞実験
    [3]

    C6 (3×105 cells/well) and U87 (1.5×105 cells/well) glioma cells are seeded onto 96-well microplate and cultured 24 h. PBS is added into the control group and Shikonin is added into experimental group to reach the final concentration. Cellular viability is assessed using an MTT assay after Shikonin treatment at indicated time point. The absorbance value (A) at 570 nm is read using an automatic multi-well spectrophotometer. Two groups of glioma cells from the same cell line are treated with Shikonin at lower or higher concentration, respectively; other two groups of glioma cells are treated 1 h with 100 µM Necrostatin-1 or 40 µM z-VAD-fmk prior to co-incubation with Shikonin at indicated concentration. Additionally, another two groups of glioma cells are treated only with 100 µM Necrostatin-1 or 40 µM Z-VAD-fmk at corresponding time point[3].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    動物実験

    Mice[2]
    8-10 week old male C57BL/6 mice (average weight approx.23 g) are used. Mice receive intravenous application of 200 μL PBS or radiocontrast media (RCM) via the tail vein. A single dose of Z-VAD-fmk (10 mg/kg body weight) or Necrostatin-1 (1.65 mg/kg body weight) is applied intraperitoneally 15 min. before RCM-injection. Mice are harvested another 24 hours after RCM-application (48 hours after reperfusion). Blood samples are obtained from retroorbital bleeding and serum levels of urea and creatinine are determined.

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.8561 mL 19.2805 mL 38.5609 mL 96.4023 mL
    5 mM 0.7712 mL 3.8561 mL 7.7122 mL 19.2805 mL
    10 mM 0.3856 mL 1.9280 mL 3.8561 mL 9.6402 mL
    15 mM 0.2571 mL 1.2854 mL 2.5707 mL 6.4268 mL
    20 mM 0.1928 mL 0.9640 mL 1.9280 mL 4.8201 mL
    25 mM 0.1542 mL 0.7712 mL 1.5424 mL 3.8561 mL
    30 mM 0.1285 mL 0.6427 mL 1.2854 mL 3.2134 mL
    40 mM 0.0964 mL 0.4820 mL 0.9640 mL 2.4101 mL
    50 mM 0.0771 mL 0.3856 mL 0.7712 mL 1.9280 mL
    60 mM 0.0643 mL 0.3213 mL 0.6427 mL 1.6067 mL
    80 mM 0.0482 mL 0.2410 mL 0.4820 mL 1.2050 mL
    100 mM 0.0386 mL 0.1928 mL 0.3856 mL 0.9640 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Necrostatin-1 Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Necrostatin-14311-88-0Nec-1Necrostatin1Necrostatin 1Nec1Nec 1RIP kinaseAutophagyIndoleamine 2,3-Dioxygenase (IDO)FerroptosisNecroptosisReceptor-interacting protein kinasesRIPKInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Necrostatin-1
    製品番号:
    HY-15760
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.